tiprankstipranks
Advertisement
Advertisement

GB:0QW0 Stock Latest News

Argenx price target raised to $1,059 from $1,007 at Evercore ISI
The FlyArgenx price target raised to $1,059 from $1,007 at Evercore ISI
6d ago
ARGX
Argenx price target raised to $1,016 from $1,013 at BofA
PremiumThe Fly
Argenx price target raised to $1,016 from $1,013 at BofA
10d ago
ARGX
Myles Minter Reiterates Buy as Vyvgart’s Expanded FDA Label and Attractive Valuation Support Continued Growth
PremiumRatings
Myles Minter Reiterates Buy as Vyvgart’s Expanded FDA Label and Attractive Valuation Support Continued Growth
10d ago
ARGX
Argenx: FDA approves label expansion for Vyvgart, Vvygart Hytrulo
PremiumThe Fly
Argenx: FDA approves label expansion for Vyvgart, Vvygart Hytrulo
12d ago
ARGX
Argenx price target lowered to $1,170 from $1,230 at Morgan Stanley
PremiumThe Fly
Argenx price target lowered to $1,170 from $1,230 at Morgan Stanley
13d ago
ARGX
Argenx price target raised to $1,135 from $1,120 at Guggenheim
PremiumThe FlyArgenx price target raised to $1,135 from $1,120 at Guggenheim
13d ago
ARGX
Argenx price target raised to $1,260 from $1,247 at Wells Fargo
Premium
The Fly
Argenx price target raised to $1,260 from $1,247 at Wells Fargo
13d ago
ARGX
Argenx price target lowered to $1,222 from $1,227 at Stifel
Premium
The Fly
Argenx price target lowered to $1,222 from $1,227 at Stifel
13d ago
ARGX
Argenx Maintains Buy Rating on Vyvgart Momentum, Robust Profitability, and Expanding Late-Stage Pipeline
PremiumRatings
Argenx Maintains Buy Rating on Vyvgart Momentum, Robust Profitability, and Expanding Late-Stage Pipeline
14d ago
ARGX
Argenx announces Phase 3 Adapt Oculus study met primary endpoint
PremiumThe Fly
Argenx announces Phase 3 Adapt Oculus study met primary endpoint
1M ago
ARGX
Argenx price target lowered to $1,014 from $1,060 at Oppenheimer
PremiumThe Fly
Argenx price target lowered to $1,014 from $1,060 at Oppenheimer
2M ago
ARGX
Argenx added to European Conviction List at Goldman Sachs
PremiumThe Fly
Argenx added to European Conviction List at Goldman Sachs
2M ago
ARGX
Argenx upgraded to Buy from Hold at Deutsche Bank
PremiumThe FlyArgenx upgraded to Buy from Hold at Deutsche Bank
2M ago
ARGX
Deutsche Bank upgrades Argenx on Vyvgart momentum, less-demanding valuation
Premium
The Fly
Deutsche Bank upgrades Argenx on Vyvgart momentum, less-demanding valuation
2M ago
ARGX
Argenx price target lowered to $890 from $925 at RBC Capital
Premium
The Fly
Argenx price target lowered to $890 from $925 at RBC Capital
3M ago
ARGX
Argenx price target lowered to $890 from $925 at RBC Capital
PremiumThe Fly
Argenx price target lowered to $890 from $925 at RBC Capital
3M ago
ARGX
Argenx price target raised to $867 from $858 at Baird
PremiumThe Fly
Argenx price target raised to $867 from $858 at Baird
3M ago
ARGX
Argenx price target lowered to $1,120 from $1,160 at Guggenheim
PremiumThe Fly
Argenx price target lowered to $1,120 from $1,160 at Guggenheim
3M ago
ARGX
Argenx price target lowered to $1,247 from $1,317 at Wells Fargo
PremiumThe Fly
Argenx price target lowered to $1,247 from $1,317 at Wells Fargo
3M ago
ARGX
Argenx price target raised to $940 from $915 at H.C. Wainwright
PremiumThe FlyArgenx price target raised to $940 from $915 at H.C. Wainwright
3M ago
ARGX
Argenx price target raised to $944 from $925 at Citizens
Premium
The Fly
Argenx price target raised to $944 from $925 at Citizens
3M ago
ARGX
Argenx price target lowered to $1,227 from $1,248 at Stifel
Premium
The Fly
Argenx price target lowered to $1,227 from $1,248 at Stifel
3M ago
ARGX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >